

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

COMPLETION OF TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcement dated 20 July 2024 (the “**Top-up Subscription Announcement**”) issued by China Biotech Services Holdings Limited (the “**Company**”) in relation to, among other things, the top-up subscription of new shares of the Company. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Top-up Subscription Announcement.

COMPLETION OF THE TOP-UP SUBSCRIPTION AGREEMENT

The Company is pleased to announce that all conditions precedent under the Top-up Subscription Agreement were fulfilled and the Top-up Subscription Completion took place on 31 July 2024. Pursuant to the Top-up Subscription Agreement, an aggregate of 12,500,000 Top-up Subscription Shares have been allotted and issued to Genius Lead at the Top-up Subscription Price of HK\$0.40 per Top-up Subscription Share under the General Mandate. The aggregate net proceeds of the Top-up Subscription, after deduction of expenses, are estimated to be approximately HK\$4,600,000. The Company intends to apply the net proceeds for general working capital of the Group.

EFFECTS ON THE SHAREHOLDING STRUCTURE

The total number of 12,500,000 Top-up Subscription Shares allotted and issued under the Top-up Subscription represents (i) approximately 1.30% of the issued share capital of the Company immediately before the Top-up Subscription Completion; and (ii) approximately 1.28% of the issued share capital of the Company as enlarged by the allotment and issue of the Top-up Subscription Shares.

Set out below is the shareholding structure of the Company (i) immediately before the Top-up Subscription Completion; and (ii) as at the date of this announcement (immediately after the Top-up Subscription Completion):

Shareholders	Immediately before the Top-up Subscription Completion		As at the date of this announcement (immediately after the Top-up Subscription Completion)	
	No. of Shares	Approximate % of issued Shares	No. of Shares	Approximate % of issued Shares
Genius Lead	517,000,546	53.67%	529,500,546	54.27%
Mr. Liu (<i>Note</i>)	1,092,000	0.11%	1,092,000	0.11%
Sub-total	518,092,546	53.78%	530,592,546	54.38%
<i>Public Shareholders</i>				
The Placee	14,230,000	1.48%	14,230,000	1.46%
Other public Shareholders	430,908,604	44.74%	430,908,604	44.16%
Sub-total	445,138,604	46.22%	445,138,604	45.62%
Total	963,231,150	100.00%	975,731,150	100.00%

Note: Mr. Liu is the sole director of Genius Lead and also indirectly holds all the issued shares in Genius Lead through Genius Earn Limited.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 31 July 2024

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.